The aim of my thesis is to improve outcomes for patients with advanced ovarian cancer by revealing insights into the importance of molecular screening for ovarian tumor patients to enable clinicians to use these new diagnostic tools and provide their patients with optimal care, to predict patients who would benefit of PARP inhibitors to significantly expands the life expectancy.